Mobile website
Archive > Volume 29 Issue 12 > 2022,29(12):1125-1129. DOI:10.3872/j.issn.1007-385X.2022.12.009 Prev Next
Clinical Research
Comparative studies of the clinical efficacy and adverse reaction of treating stage ⅢⅢ/ⅣⅣ colon cancer with lienal polypeptide injection combined with FOLFOX4 or XELOX
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To examine the efficacy and safety of lienal polypeptide injection combined with FOLFOX4 or XELOX in the treatment of stage Ⅲ/Ⅳ colon cancer. Methods: One hundred and sixty patients who underwent a curative resection of colon cancer in the Sixth People's Hospital of Huizhou between January 2017 and June 2020 were included in the study. All patients were randomized into 2 groups of 80 each: patients who received lienal polypeptide injection combined with FOLFOX4 (lienal polypeptide + FOLFOX4 group) and patients who received lienal polypeptide injection combined with XELOX (lienal polypeptide + XELOX group). All patients were given six rounds of treatment. Two-year follow-up assessments of the clinical efficacy, immunity, nutritional status, quality of life and toxicity or adverse effects were conducted 1 months after the end of treatment. Results: Compared with the lienal polypeptide + FOLFOX4 group, the disease control rate (DCR) and objective response rate (ORR) of the lienal polypeptide+XELOX group were dramatically improved (all P<0.05). The percentage of CD3+ T cells, CD4+ T cells and NK cells, the EORTC QLQ-C30 scores and the level of PNI in the lienal polypeptide+XELOX group were higher (all P<0.05). NLR, LMR, CA125, CA199, and CEA were significantly decreased (all P<0.05). In terms of adverse effects, the incidence of leukopenia, neutropenia, neurotoxicity, oral mucositis, and hand foot syndrome in the lienal polypeptide + XELOX group were remarkably decreased compared with the lienal polypeptide + FOLFOX4 group (all P<0.05). No difference in progression-free survival (PFS) and overall survival (OS) was detectable (all P>0.05). Conclusion: Compared with lienal polypeptide injection combined with FOLFOX4, lienal polypeptide injection combined with XELOX has a significant advantage in decreasing the incidence of adverse events and improving the quality of life of Ⅲ/Ⅳ colon cancer patients.
Keywords:
Project Supported:
Clc Number:
